Clinical Trial Update: VIsceral Fat Reduction Assessed by CT-scan On RImonabAnt [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating visceral fat reduction with RimonabAnt in metabolic syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Syndrome

Drugs mentioned

• Rimonabant (rimonabant)

Snippet

Sponsor: Sanofi | Conditions: Metabolic Syndrome | Phase 3 | Status: COMPLETED